Surreal illustration of a healthy kidney protected by digital data, symbolizing research on diabetes and kidney disease.

Kidney Transplants and Diabetes: What's the Real Risk?

Kai Mendoza in Health & Wellness December 2025 • 4 min read.

"A new study sheds light on diabetic nephropathy after kidney transplantation, offering hope and insights for patients with type II diabetes."

For individuals battling end-stage renal disease (ESRD), kidney transplantation stands as a beacon of hope, offering an improved quality of life and increased survival rates. However, for those with type II diabetes, a leading cause of ESRD, the journey doesn't end with the transplant. These patients face a unique challenge: the risk of developing diabetic nephropathy (DN) in their new kidney.

Diabetic nephropathy, a condition where diabetes damages the kidneys, can recur or develop de novo after transplantation, threatening the long-term success of the transplant. Understanding the true risk and natural history of post-transplantation DN is critical for optimizing patient care and improving outcomes. Unfortunately, existing research has been limited, often failing to distinguish between different types of diabetes and overlooking new-onset diabetes after transplantation (NODAT).

A recent retrospective case series study from a high-volume center in the United States aims to fill this gap in knowledge. By analyzing kidney transplant biopsies and patient data, researchers have provided valuable insights into the incidence, progression, and risk factors associated with DN after kidney transplantation in patients with pre-existing type II diabetes. This article will delve into the study's findings, exploring the implications for patients, transplant physicians, and the future of kidney transplant care.

What Does the Research Say About Diabetic Nephropathy After Kidney Transplant?

Surreal illustration of a healthy kidney protected by digital data, symbolizing research on diabetes and kidney disease.

Researchers at a major medical center queried their biopsy database to find kidney transplant biopsies showing evidence of DN. They looked at the time it took for DN to be diagnosed after the transplant (time to diagnosis, or TTD) and analyzed it alongside factors like patient demographics, creatinine levels, and when their diabetes started. By looking at how many patients developed DN in the last couple of years, they estimated how often DN recurs.

The study identified sixty patients who met the criteria for having DN after kidney transplant. The average age of these patients was 56.6 years, and their average creatinine level at the time of biopsy was 1.65 mg/dL. It was common to find other issues during the kidney biopsy, with rejection occurring at various rates:

Class I: 5.0%
Class IIA: 66.7%
Class IIB: 18.4%
Class III: 10%

The average time to diagnosis (TTD) was 1456 days. Patients who received a kidney from a deceased donor developed DN faster than those who received a kidney from a living donor (1118 days vs. 2470 days). Older patients and those with higher creatinine levels also had shorter TTDs. Extrapolating the data suggests that about 74.7% of patients would be free of DN 10 years after their kidney transplant.

Looking Ahead: What This Means for Kidney Transplant Patients

The study's findings offer both reassurance and a call to action. While diabetic nephropathy remains a risk after kidney transplantation, the study suggests that the majority of patients with type II diabetes can remain free of DN for at least 10 years. This highlights the importance of continued monitoring, proactive management of diabetes, and close collaboration between patients and their transplant teams. Further research is needed to refine risk prediction, optimize immunosuppression strategies, and develop targeted therapies to prevent or delay the onset of DN after kidney transplantation, ultimately ensuring the long-term success of this life-saving procedure.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1111/ctr.13425, Alternate LINK

Title: Diabetic Nephropathy After Kidney Transplantation In Patients With Pretransplantation Type Ii Diabetes: A Retrospective Case Series Study From A High-Volume Center In The United States

Subject: Transplantation

Journal: Clinical Transplantation

Publisher: Wiley

Authors: Arielle Cimeno, Jennifer Munley, Cinthia Drachenberg, Matthew Weir, Abdolreza Haririan, Jonathan Bromberg, Rolf N. Barth, Joseph R. Scalea

Published: 2018-11-04

Everything You Need To Know

What is diabetic nephropathy and how does it relate to kidney transplants for people with type II diabetes?

After a kidney transplant, individuals with type II diabetes face the risk of developing diabetic nephropathy (DN) in the transplanted kidney. Diabetic nephropathy is a condition where diabetes damages the kidneys. It can either be a recurrence of the original condition or develop as new-onset diabetic nephropathy (de novo). The study highlights that while it is a risk, most patients can remain free of diabetic nephropathy for at least 10 years post-transplant. Factors such as the source of the kidney (deceased vs. living donor), age, and creatinine levels can influence the time to diagnosis of diabetic nephropathy.

How does the source of the transplanted kidney (living vs. deceased donor) affect the development of diabetic nephropathy after a kidney transplant?

The study indicates that the source of the kidney affects the time it takes for diabetic nephropathy to be diagnosed after a transplant. Patients who received kidneys from deceased donors developed diabetic nephropathy faster than those who received kidneys from living donors. The average time to diagnosis was 1118 days for deceased donors versus 2470 days for living donors. This difference is significant because it suggests that the origin of the transplanted kidney influences the risk and progression of diabetic nephropathy.

How did researchers determine the risk and progression of diabetic nephropathy in patients with type II diabetes after kidney transplantation?

The research analyzed kidney transplant biopsies and patient data to understand the incidence, progression, and risk factors of diabetic nephropathy in type II diabetes patients post-transplant. Researchers looked at how many patients developed DN in the last couple of years, they estimated how often DN recurs. By examining factors such as patient demographics, creatinine levels, and when their diabetes started, the study identified sixty patients who met the criteria for having DN after kidney transplant. The average time to diagnosis was 1456 days.

Why is it important to study diabetic nephropathy in the context of kidney transplants for individuals with type II diabetes?

While kidney transplantation offers an improved quality of life and increased survival rates, it's not without its risks, especially for those with type II diabetes. The major concern is the potential development of diabetic nephropathy, which can threaten the long-term success of the transplant. The significance lies in understanding how to optimize patient care, including continued monitoring and proactive management of diabetes, to mitigate this risk. The study’s estimation that about 74.7% of patients would be free of DN 10 years after their kidney transplant is a valuable, actionable data point.

What steps can be taken after a kidney transplant to reduce the risk of diabetic nephropathy in patients with type II diabetes?

The findings suggest the importance of continued monitoring, proactive management of diabetes, and close collaboration between patients and their transplant teams. Monitoring is key to ensure long-term kidney health. Further research is needed to refine risk prediction, optimize immunosuppression strategies, and develop targeted therapies to prevent or delay the onset of diabetic nephropathy after kidney transplantation.